Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02034110
Title Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

thyroid gland cancer

gastrointestinal stromal tumor

biliary tract cancer

germ cell cancer

multiple myeloma

high grade glioma

hairy cell leukemia

small intestine adenocarcinoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST